Circulating concentrations of hemostatic factors and two "steroid sensitive proteins" during oral hormone replacement therapy in women with coronary heart disease

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 64, Issue 7, 2004, Pages 659-666

  Pripp, U ^a   Schenck Gustafsson, K ^a   Landgren, B M ^a   Carlström, Kjell ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular risk; Corticosteroid binding globulin; Hemostatic factors; Hormone replacement therapy; Postmenopause; Sex hormone binding globulin

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING INHIBITOR; CONJUGATED ESTROGEN; D DIMER; ESTROGEN; FIBRIN; FIBRINOGEN; HYDROCORTISONE; MEDROXYPROGESTERONE ACETATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SEX HORMONE BINDING GLOBULIN; STEROID; TESTOSTERONE; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TRANSCORTIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EQUIDAE;

EID: 7044241168     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510410002995     Document Type: Article

References (27)

1. Henriksson P, Blombäck M, Eriksson A, Stege R, Carlström K. Effects of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol 1990; 65: 282-5.
2. Eriksson-Berg M, Silveira A, Orth-Gomér K, Hamsten A, Schenck-Gustafsson K. Coagulation factor VII in middle-aged women with and without coronary heart disease. Thromb Haemost 2002; 85: 787-92.
3. De Pergola G, De Mitrio V, Perricci A. Influence of free testosterone on antigen levels of plasminogen activator inhibitor-1 in premenopausal women with central obesity. Metabolism 1992; 41: 131-4.
4. Laurell C-B, Rannevik G. A comparison of plasma protein changes induced by danazol, pregnancy, and estrogens. J Clin Endocrinol Metab 1979; 49: 719-25.
5. Von Schoultz B, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette A, Stege R. Estrogen therapy and liver function: metabolic effects of oral and parenteral administration. The Prostate 1989; 14: 389-95.
6. Lapidus L, Lindstedt G, Lundberg PA, Bengtsson C, Gredmark T. Concentrations of sex-hormone binding globulin and corticosteroid binding globulin in serum in relation to cardiovascular risk factors and to 12-year incidence of cardiovascular disease and overall mortality in postmenopausal women. Clin Chem 1986; 32: 146-52.
7. Svendsen OL, Hassager C, Christiansen C, Nielsen JD, Winther K. Plasminogen activator inhibitor-1, tissue-type plasminogen activator and fibrinogen: effect of dieting with or without exercise in overweight postmenopausal women. Arterioscler Thromb Vasc Biol 1996; 16: 381-5.
8. Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002; 81: 482-90.
9. Writing group for the Women's Health Initiative Investigators. Risks and benefit of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002; 288: 321-33.
10. Hall G, Pripp U, Schenck-Gustafsson K, Landgren B-M. Long-term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas 1998; 28: 235-42.
11. Pripp U, Hall G, Csemiczky G, Eksborg S, Landgren B-M, Schenck-Gustafsson K. A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease. J Hypertens 1999; 17: 1379-86.
12. Nowinski K, Pripp U, Carlström K, Landgren B-M, Schenck-Gustafsson K, Bergfeldt L. Repolarization measures and their relation to sex hormones in postmenopausal women with cardiovascular disease receiving hormone replacement therapy. Am J Cardiol 2002; 90: 1050-5.
13. Tryding N, Tufvesson C, Sonntag S. Drug effects in clinical chemistry. Stockholm: Swedish Society for Clinical Chemistry, the National Corporation of Swedish Pharmacies and Pharmasoft AB. Apoteksbolaget, Förlagsavdelningen; 1996.
14. Vermylen C, de Vreker R, Verstraete M. A rapid enzymatic method for assay of fibrinogen: fibrin polymerization time (FPT) test. Clin Chim Acta 1963; 8: 418-24.
15. Södergård R, Bäckström T, Shanbag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17β to plasma proteins at body temperature. J Steroid Biochem 1982; 18: 801-4.
16. Poretsky L. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocrine Rev 1991; 12: 3-13.
17. Bastard JP, Pieroni L, Hainque B. Relationship between plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev 2000; 16: 192-201.
18. Banfi C, Eriksson P, Glandomenico G. Transcriptional regulation of plasminogen activator inhibitor 1 gene by insulin: insights into the signalling pathway. Diabetes 2001; 50: 1522-30.
19. Prandota J, Pankow-Prandota L, Koiecki L. Impaired activation of the fibrinolytic system in children with Henoch-Schönlein purpura: beneficial effect of hydrocortisone plus sigma-aminocaproic acid therapy on disappearance rate of cutaneous vasculitis and fibrinolysis. Am J Ther 2001; 8: 11-9.
20. Kilger E, Weis F, Briegel J, Frey L, Goetz AE, Reuter D, Nagy A, Schuetz A, Lamm P, Knoll A, Petger K. Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery. Crit Care Med 2003; 31: 1068-74.
21. Yardumian A, Machin SJ. Hypercoagulable states. Int Anesthesiol Clin 1985; 23: 1441-55.
22. Thornton AD, Gelehrter TD. Human hepatocytes express the gene for type 1 plasminogen activator inhibitor (PAI-1) in vivo. Fibrinolysis 1995; 9: 9-15.
23. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in human hepatoma (HepG2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988; 67: 460-4.
24. Kilbourne EJ, Scicchitano MS. The activation of plasminogen activator inhibitor 1 expression: IL 1 beta is attenuated by estrogen in hepatoblastoma HepEG2 cells expressing estrogen receptor alpha. Thromb Haemost 1999; 81: 423-7.
25. Lundgren S, Lønning PE, Utaaker E, Aakvaag A, Kvinsland S. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-I. General findings. J Steroid Biochem 1990; 36: 99-104.
26. Henrikson P, Blombäck M, Bratt G, Edhag O, Eriksson A. Activators and inhibitors of coagulation and fibrinolysis in patients with prostatic cancer treated with oestrogen or orchidectomy. Thrombosis Res 1986; 44: 783-91.
27. Van Rooijen M, von Schoultz B, Silveira A, Hamsten A, Bremme K. Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII. Am J Obstet Gynecol 2002; 186: 44-8.